MedTrace Logo

A Study of MDX-1100 in Subjects With Active Ulcerative Colitis

NCT00656890 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2015-10-12

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of the MDX-1100 regimen in subjects with active Ulcerative colitis(UC) and determine the response rate at day 57 in patients administered MDX-1100.

Conditions

Interventions

BIOLOGICAL

sterile saline for injection

10mg/kg/dose sterile saline injected every other week for a total of 4 doses

BIOLOGICAL

MDX-1100

10mg/kg/dose MDX-1100 injected every other week for a total of 4 doses

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States
  • Canada
  • Czechia
  • Hungary
  • Latvia
  • Romania
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00656890 on ClinicalTrials.gov